BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9107427)

  • 1. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix.
    Shah KV; Viscidi RP; Alberg AJ; Helzlsouer KJ; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):233-7. PubMed ID: 9107427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
    Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Walboomers JM; Meijer CJ; Shah KV; Clayman B; Viscidi RP
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):935-40. PubMed ID: 10548324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
    Rocha-Zavaleta L; Ambrosio JP; Mora-Garcia ML; Cruz-Talonia F; Hernandez-Montes J; Weiss-Steider B; Ortiz-Navarrete V; Monroy-Garcia A
    J Gen Virol; 2004 Sep; 85(Pt 9):2643-2650. PubMed ID: 15302958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seric and local antibodies against a synthetic peptide of HPV16.
    Dreyfus M; Baldauf JJ; Ritter J; Obert G
    Eur J Obstet Gynecol Reprod Biol; 1995 Apr; 59(2):187-91. PubMed ID: 7657014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.
    Sasagawa T; Inoue M; Lehtinen M; Zhang W; Gschmeissner SE; Hajibagheri MA; Finch J; Crawford L
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):403-10. PubMed ID: 8807204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.
    Marais D; Rose RC; Williamson AL
    J Med Virol; 1997 Feb; 51(2):126-31. PubMed ID: 9021543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
    Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
    Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles.
    Tachezy R; Hamsíková E; Hájek T; Mikysková I; Smahel M; Van Ranst M; Kanka J; Havránková A; Rob L; Guttner V; Slavík V; Anton M; Kratochvíl B; Kotrsová L; Vonka V
    J Med Virol; 1999 Aug; 58(4):378-86. PubMed ID: 10421405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin E expression and early cervical neoplasia in ThinPrep specimens. A feasibility study.
    Weaver EJ; Kovatich AJ; Bibbo M
    Acta Cytol; 2000; 44(3):301-4. PubMed ID: 10833982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia.
    Marais DJ; Rose RC; Lane C; Kay P; Nevin J; Denny L; Soeters R; Dehaeck CM; Williamson AL
    J Med Virol; 2000 Apr; 60(4):403-10. PubMed ID: 10686023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal expression of galactosyl(alpha 1-->3) galactose epitopes in squamous cells of the uterine cervix infected by human papillomavirus.
    Tremont-Lukats IW; Avila JL; Tapia F; Hernández D; Cáceres-Dittmar G; Rojas M
    Pathobiology; 1996; 64(5):239-46. PubMed ID: 9068006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1).
    Heard I; Tassie JM; Schmitz V; Mandelbrot L; Kazatchkine MD; Orth G
    Obstet Gynecol; 2000 Sep; 96(3):403-9. PubMed ID: 10960634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Stukart MJ; Robbesom AA; von Blomberg-van der Flier BM; Herbrink P; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    Int J Cancer; 1996 Dec; 68(6):731-8. PubMed ID: 8980175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
    Combita AL; Bravo MM; Touzé A; Orozco O; Coursaget P
    Int J Cancer; 2002 Feb; 97(6):796-803. PubMed ID: 11857357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan.
    Matsumoto K; Yoshikawa H; Yasugi T; Nakagawa S; Kawana K; Takeoka A; Yaegashi N; Iwasaka T; Kanazawa K; Taketani Y; Kanda T
    J Med Virol; 2003 Mar; 69(3):441-6. PubMed ID: 12526056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.
    Costa AP; Giraldo PC; Cobucci RN; Consolaro ML; Souza RP; Canário LB; Machado PR; Randall Martins R; Vieira Baptista P; Jr JE; Gonçalves AK
    Asian Pac J Cancer Prev; 2020 Sep; 21(9):2799-2804. PubMed ID: 32986383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16.
    Ellis JR; Etherington I; Galloway D; Luesley D; Young LS
    Lancet; 1997 Apr; 349(9058):1069-70. PubMed ID: 9107250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.